Johnson & Johnson Highlights New IMAAVY Data at EAN 2026
GENEVA, Switzerland, June 26, 2026 Johnson & Johnson presented 12 new scientific abstracts at the European Academy of Neurology...
gMG
Advertisement
Argenx Gains FDA Approval Expanding VYVGART to All gMG Patients
AMSTERDAM, Netherlands, May 8, 2026 Argenx SE announced that the U.S. Food and Drug Administration (FDA) has approved a...
Johnson & Johnson IMAAVY Delivers 2-Year gMG Control
HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...
Gefurulimab Shows Early and Sustained Efficacy in gMG Patients
Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...
Advertisement
